Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
mRNA-1283.251
- Development stage
- Unknown
- Lead developer
- Moderna
- Modality
- mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
mRNA-1283.251 is a next-generation mRNA vaccine formulation developed by Moderna for the prevention of COVID-19. It is a variant-specific version of the mRNA-1283 (mNEXSPIKE) platform, which utilizes lipid nanoparticle (LNP) technology to deliver mRNA encoding a chimeric SARS-CoV-2 spike protein. This chimeric antigen, designated NTD-RBD-HATM, consists of the N-terminal domain (NTD) and receptor-binding domain (RBD) of the SARS-CoV-2 spike protein anchored to an influenza hemagglutinin transmembrane domain. A significant advantage of the mRNA-1283 platform is its stability at standard refrigerated temperatures (2-5 °C), which simplifies distribution compared to first-generation mRNA vaccines requiring ultra-low temperature storage. mRNA-1283.251 is specifically designed to target circulating variants and is being evaluated in Phase 3b/4 clinical trials to assess its immunogenicity and safety in older adults and high-risk populations.
- Brand names
- mNEXSPIKE
- Other names
- Mnexspike
02
Targets
SARS-CoV-2 spike
Beyond the preview
Go deeper on mRNA-1283.251.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on mRNA-1283.251.